Search All UT System Experts

Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: A Gynecologic Oncology Group study

Agustin A. Garcia, John A. Blessing, Heinz Josef Lenz, Kathleen M. Darcy, Robert S. Mannel, David Scott Miller, Nader Husseinzadeh

Research output: Contribution to journal › Article › peer-review

15 Scopus citations

Fingerprint

Dive into the research topics of 'Phase II clinical trial of capecitabine in ovarian carcinoma recurrent 6-12 months after completion of primary chemotherapy, with exploratory TS, DPD, and TP correlates: A Gynecologic Oncology Group study'. Together they form a unique fingerprint.

Medicine & Life Sciences